Has anyone located any long-term mRNA vaccine studies done on humans without terminal diseases prior to covid-19?
The only studies I've found on mRNA vaccines were on terminally ill patients
For instance this vaccine was tested in 2015 on patients with advanced metastatic castration resistant prostate cancer. It's unclear why we've decided to treat billions of people with this novel technology when previously it's only been tested on very sick people with terminal illnesses.
>Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
>The self-adjuvanted RNActive_ vaccine CV9103 was well tolerated and immunogenic.
>The most frequent adverse events were grade 1/2 injection site erythema, injection site reactions, fatigue, pyrexia, chills and influenza-like illness. Possibly treatment related urinary retention occurred in 3 patients. The recommended dose was 1280 _g. A total of 26/33 evaluable patients treated at 1280 _g developed an immune response, directed against multiple antigens in 15 out of 33 patients. One patient showed a confirmed PSA response. In the subgroup of 36 metastatic patients, the Kaplan-Meier estimate of median overall survival was 31.4 months [95 % CI: 21.2; n.a].
>The technology is a versatile, fast and cost-effective platform allowing for creation of vaccines. The follow-up vaccine CV9104 including the additional antigens prostatic acid phosphatase (PAP) and Muc1 is currently being tested in a randomized phase IIb trial to assess the clinical benefit induced by this new vaccination approach.
They keep telling us to trust the science... where is the evidence that this treatment is safe in the long-term?
The only studies I've found on mRNA vaccines were on terminally ill patients
For instance this vaccine was tested in 2015 on patients with advanced metastatic castration resistant prostate cancer. It's unclear why we've decided to treat billions of people with this novel technology when previously it's only been tested on very sick people with terminal illnesses.
>Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
>The self-adjuvanted RNActive_ vaccine CV9103 was well tolerated and immunogenic.
>The most frequent adverse events were grade 1/2 injection site erythema, injection site reactions, fatigue, pyrexia, chills and influenza-like illness. Possibly treatment related urinary retention occurred in 3 patients. The recommended dose was 1280 _g. A total of 26/33 evaluable patients treated at 1280 _g developed an immune response, directed against multiple antigens in 15 out of 33 patients. One patient showed a confirmed PSA response. In the subgroup of 36 metastatic patients, the Kaplan-Meier estimate of median overall survival was 31.4 months [95 % CI: 21.2; n.a].
>The technology is a versatile, fast and cost-effective platform allowing for creation of vaccines. The follow-up vaccine CV9104 including the additional antigens prostatic acid phosphatase (PAP) and Muc1 is currently being tested in a randomized phase IIb trial to assess the clinical benefit induced by this new vaccination approach.
They keep telling us to trust the science... where is the evidence that this treatment is safe in the long-term?
